Literature DB >> 15960605

Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses.

Evelyn Abordo-Adesida1, Antonia Follenzi, Carlos Barcia, Sandra Sciascia, Maria G Castro, Luigi Naldini, Pedro R Lowenstein.   

Abstract

Lentiviral vectors are promising tools for gene therapy in the CNS. It is therefore important to characterize their interactions with the immune system in the CNS. This work characterizes transgene expression and brain inflammation in the presence or absence of immune responses generated after systemic immunization with lentiviral vectors. We characterized transduction with SIN-LV vectors in the CNS. A dose-response curve using SIN-LV-GFP demonstrated detectable transgene expression in the striatum at a dose of 10(2), and maximum expression at 10(6), transducing units of lentiviral vector, with minimal increase in inflammatory markers between the lowest and highest dose of vector injected. Our studies demonstrate that injection of a lentiviral vector into the CNS did not cause a measurable inflammatory response. Systemic immunization after CNS injection, with the lentiviral vector expressing the same transgene as a vector injected into the CNS, caused a decrease in transgene expression in the CNS, concomitantly with an infiltration of inflammatory cells into the CNS parenchyma at the injection site. However, peripheral immunization with a lentiviral vector carrying a different transgene did not diminish transgene expression, or cause CNS inflammation. Systemic immunization preceding injection of lentiviral vectors into the CNS determined that preexisting antilentiviral immunity, regardless of the transgene, did not affect transgene expression. Furthermore, we showed that the transgene, but not the virion or vector components, is responsible for providing antigenic epitopes to the activated immune system, on systemic immunization with lentivirus. Low immunogenicity and prolonged transgene expression in the presence of preexisting lentiviral immunity are encouraging data for the future use of lentiviral vectors in CNS gene therapy. In summary, the lentiviral vectors tested induced undetectable activation of innate immune responses, and stimulation of adaptive immune responses against lentiviral vectors was effective in causing a decrease in transgene expression only if the immune response was directed against the transgene. A systemic immune response against vector components alone did not cause brain inflammation, possibly because vector-derived epitopes were not being presented in the CNS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15960605      PMCID: PMC2676203          DOI: 10.1089/hum.2005.16.741

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  30 in total

1.  Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types.

Authors:  Clare E Thomas; Penny Edwards; Thomas J Wickham; Maria G Castro; Pedro R Lowenstein
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 2.  Viral interference with antigen presentation.

Authors:  Jonathan W Yewdell; Ann B Hill
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 3.  Immune response following intraocular delivery of recombinant viral vectors.

Authors:  J Bennett
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

Review 4.  Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.

Authors:  K Jooss; N Chirmule
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

5.  Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

Authors:  Clare E Thomas; Theresa A Storm; Zan Huang; Mark A Kay
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

6.  Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice.

Authors:  Diana Zala; Jean-Charles Bensadoun; Luis Pereira de Almeida; Blair R Leavitt; Claire-Anne Gutekunst; Patrick Aebischer; Michael R Hayden; Nicole Déglon
Journal:  Exp Neurol       Date:  2004-01       Impact factor: 5.330

7.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Authors:  Mimoun Azzouz; G Scott Ralph; Erik Storkebaum; Lucy E Walmsley; Kyriacos A Mitrophanous; Susan M Kingsman; Peter Carmeliet; Nicholas D Mazarakis
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

8.  Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.

Authors:  Carmen S Peden; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.

Authors:  Antonia Follenzi; Manuela Battaglia; Angelo Lombardo; Andrea Annoni; Maria Grazia Roncarolo; Luigi Naldini
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

10.  Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells.

Authors:  Alessandra Biffi; Michele De Palma; Angelo Quattrini; Ubaldo Del Carro; Stefano Amadio; Ilaria Visigalli; Maria Sessa; Stefania Fasano; Riccardo Brambilla; Sergio Marchesini; Claudio Bordignon; Luigi Naldini
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

View more
  52 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo.

Authors:  Stéphanie Philippe; Chamsy Sarkis; Martine Barkats; Hamid Mammeri; Charline Ladroue; Caroline Petit; Jacques Mallet; Che Serguera
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-09       Impact factor: 11.205

Review 3.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

4.  Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Authors:  Sid P Kerkar; Luis Sanchez-Perez; Shicheng Yang; Zachary A Borman; Pawel Muranski; Yun Ji; Dhanalakshmi Chinnasamy; Andrew D M Kaiser; Christian S Hinrichs; Christopher A Klebanoff; Christopher D Scott; Luca Gattinoni; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

Review 5.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

6.  Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes.

Authors:  E Keen-Rhinehart; V Michopoulos; D J Toufexis; E I Martin; H Nair; K J Ressler; M Davis; M J Owens; C B Nemeroff; M E Wilson
Journal:  Mol Psychiatry       Date:  2008-08-12       Impact factor: 15.992

Review 7.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

Review 8.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

Review 9.  Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.

Authors:  Joshua Kuruvilla; Andrew Octavian Sasmita; Anna Pick Kiong Ling
Journal:  Neurol Sci       Date:  2018-08-03       Impact factor: 3.307

Review 10.  Advances in oncolytic virus therapy for glioma.

Authors:  Amy Haseley; Christopher Alvarez-Breckenridge; Abhik Ray Chaudhury; Balveen Kaur
Journal:  Recent Pat CNS Drug Discov       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.